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The c.)1639G > A polymorphism of the VKORC1 gene is a major
determinant of the response to acenocoumarol in
anticoagulated patients
The coumarin derivative acenocoumarol is widely used to
prevent recurrent arterial and venous thrombosis in European
and Latin-American countries. The appropriate dose varies
greatly and it is difficult to predict on an individual basis.
Although this may partly be due to environmental factors, i.e.
simultaneous exposure to other drugs that interfere with the
metabolism of acenocoumarol, dietary habits or other health
conditions, the inter-individual variability is thought to be
largely determined by hereditary factors (Meyer, 2000). Among
the genetic determinants, the variants c.430C > T (Arg144Cys)
and c.1075A > C (Ile359Leu) of cytochrome P450 2C9
(CYP2C9), involved in the metabolism of warfarin and
acenocoumarol, have been shown to influence the anticoagu-
lant dosage (Aithal et al, 1999; Daly & King, 2005). Progress
has recently been made in our knowledge of the vitamin K
cycle: the gene coding for the enzyme responsible for the
transformation of vitamin K 2,3-epoxide to vitamin
K-hydroquinone has been cloned (Li et al, 2004; Rost et al,
2004). Vitamin K-hydroquinone is the co-factor for the
carboxylase that adds a molecule of carbon dioxide to glutamic
acid, producing c-carboxyglutamic acid (c-Glu). The c-Glu
residues are essential for some clotting factors, such as factors
II, VII, IX, X and protein C, S and Z, to bind phospholipids
and thus be functional. The enzyme, called vitamin K-epoxide
reductase (VKORC1), is the target of the coumarin derivatives.
Importantly, several genetic variations of the VKORC1 gene
have been found to influence sensitivity to warfarin (Rost et al,
2004; D’Andrea et al, 2005; Geisen et al, 2005; Quteineh et al,
2005; Rieder et al, 2005). Twenty-eight polymorphisms have
been described in this gene, three main haplotypes covering
almost the whole genetic variability of VKORC1. VKORC1*2
haplotype has been found to account for most of the variability
in response to oral anticoagulants (Geisen et al, 2005; Rieder
et al, 2005; Sconce et al, 2005; Yuan et al, 2005). The
Ramo´n Montes,1 Estefanı´a Ruiz de
Gaona, 1 Miguel A´ngel Martı´nez-
Gonza´lez,2 Ignacio Alberca3 and Jose´
Hermida1
1Laboratory of Thrombosis and Haemostasis,
Haematology Department and Division of
Cardiovascular Sciences, Centre for Applied
Medical Research, Clı´nica Universitaria/School of
Medicine, University of Navarra, 2Department of
Preventive Medicine and Public Health, School of
Medicine, University of Navarra, Pamplona, and
3Department of Haematology, University Hospital
of Salamanca, Salamanca, Spain
Received 7 November 2005; accepted for
publication 12 January 2006
Correspondence: Jose´ Hermida MD PhD,
Laboratory of Thrombosis and Haemostasis,
Centre for Applied Medical Research, University
of Navarra, C/Pı´o XII, 55, 3rd floor, 31008
Pamplona, Spain. E-mail: jhermida@unav.es
Summary
Much of the variability in the sensitivity to warfarin in anticoagulated
patients is associated with the c.)1639G > A polymorphism of the vitamin
K-epoxide reductase (VKORC1) gene. However, its association with the
acenocoumarol dose in patients under anticoagulant therapy has not been
studied. The c.)1639G > A genotype of VKORC1 was determined in 113
patients on stable anticoagulation requiring low (n ¼ 42), medium (n ¼ 42)
or high (n ¼ 21) acenocoumarol doses. To evaluate the association between
acenocoumarol requirements and the c.)1639G > A variant, multivariate
logistic regression models were fitted, adjusting for age, gender, and the
c.430C > T and c.1075A > C variants of cytochrome P450 2C9 (CYP2C9). A
total of 90Æ5% of the patients in the low acenocoumarol dose group carried
the A allele of VKORC1:c.)1639G > A. The A allele independently increased
the odds of requiring a low acenocoumarol dose [odds ratio (OR) 9Æ4; 95%
confidence interval (CI) 1Æ9–46Æ4; P ¼ 0Æ006], especially when the
homozygous form was present (OR 44Æ2; 95% CI 5Æ5–354Æ6; P < 0Æ001).
The A allele was less frequent in the high dose group showing an inverse
association with the requirement for high doses (OR 0Æ04; 95% CI 0Æ01–0Æ22;
P < 0Æ001). The A allele of the c.)1639G > A polymorphism of VKORC1 is
therefore associated with a low-dose requirement for acenocoumarol in
patients receiving anticoagulant therapy.
Keywords: vitamin K, drugs, anticoagulation.
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c.)1639G > A polymorphism marks the VKORC1*2 haplotype
(Geisen et al, 2005), and its association with increased
response to acenocoumarol has been shown in a group of
healthy subjects (Bodin et al, 2005). However, its influence in
patients receiving acenocoumarol treatment have not been
studied to date. Our aim was to study the effect of the
c.)1639G > A polymorphism on the acenocoumarol dosage
requirements in a group of patients under stable anticoagu-
lation.
Materials and methods
Participants
A total of 113 outpatients attending the Hospital Clı´nico
Universitario de Salamanca (Spain) between January and
October 2001 who had maintained stable anticoagulation
[International normalised ratio (INR) between 2 and 3Æ2] with
acenocoumarol for at least 3 months were included in the
study. We considered a patient on stable anticoagulation as
one whose acenocoumarol dose requirement had remained
constant for at least the previous 3 months, and this dose was
the same (variation <25%) as the mean annual dose, and was
enough to keep the INR within therapeutic ranges. Two
patients with liver disease and two patients with thyroid
disease were excluded. Four patients could not be analysed.
The final population consisted of 42 consecutive patients
requiring a low acenocoumarol dose (7 mg/week or less), 42
consecutive patients requiring a medium dose (>7 mg and
<28 mg per week) and 21 consecutive patients requiring a high
dose (28 mg/week or more). Low, medium and high weekly
dose categories were arbitrarily chosen, taking into account the
fact that around 80% of subjects in our population of patients
under anticoagulation need a dose within the range defined as
the medium dose (Hermida et al, 2002).
Data concerning age, sex, weekly dose required, exposure to
other drugs affecting the acenocoumarol metabolism and the
genotype of the c.430C > T and c.1075A > C variants of
CYP2C9 were recorded as described elsewhere (Hermida et al,
2002). All subjects had given informed consent to participate
in the study.
VKORC1:c.)1639G > A genotyping
Genotyping was done by polymerase chain reaction followed
by digestion with Msp1 (New England Biolabs, Ipswich, MA,
USA) according to described methods with minor modifica-
tions (Sconce et al, 2005). The forward and reverse primers
were 5¢-GCCAGCAGGAGAGGGAAATA-3¢ and 5¢-AG-
TTTGGACTACAGGTGCCT-3¢ respectively.
Statistical analysis
In order to evaluate the association between acenocoumarol
requirements and the presence of the A allele at the )1639
position in the VKORC1 gene, multivariable logistic regression
models were fitted after adjusting for age, gender and the
presence of other polymorphisms (CYP2C9:c.430C > T and
c.1075A > C). We fitted two separate models. In both cases,
the reference category was the group requiring a medium dose
of acenocoumarol. In the first model, we estimated the odds
ratio (OR) for requiring a low dose (excluding those with a
requirement for a high dose). In the second model, we
estimated the OR for requiring a ‘high’ dose (excluding those
with a requirement for a low dose).
In the case of the CYP2C9:c.430C > T and c.1075A > C
polymorphisms, heterozygous and homozygous subjects for
the allelic variants were merged in the same category due to the
low prevalence of homozygous subjects.
A linear regression model was also performed to assess the
effect of the A allele of VKORC1:c.)1639G > A on the weekly
dose of acenocoumarol (as a continuous variable) within the
low dose group.
Interaction (effect modification) was assessed by introdu-
cing product-terms in the logistic regression models and
considering any P-value < 0Æ05 for the likelihood ratio test of
this product-term as evidence of a significant interaction.
In order to assess the proportion of carriers of both
VKORC1:c.)1639G > A and c.1075A > C polymorphisms
requiring a low acenocoumarol dose, we used exact methods
[exact binomial confidence intervals (CI) and exact Fisher
test]. Statistical analyses were performed with stata v9
software (StataCorp LP, College Station, TX, USA).
Results
Effect of VKORC1:c.)1639G > A on acenocoumarol
dosage requirement
The distribution of the G and A alleles of c.)1639G > A
polymorphism is shown in Table I. The allelic distribution was
different across the various acenocoumarol dosage groups.
Remarkably, in the group of 42 patients who maintained stable
anticoagulation with a low dose of acenocoumarol, 38 patients
Table I. Frequency of the different genotypes for the c.–1639G > A
polymorphism of the VKORC1 gene in three groups of patients with
different acenocoumarol requirements.
Acenocoumarol dose requirement
Low dose
(n ¼ 42)
Medium dose
(n ¼ 42)
High dose
(n ¼ 21)
GG 4 (9Æ5%) 10 (23Æ8%) 15 (71Æ4%)
GA 12 (28Æ6%) 24 (57Æ1%) 6 (28Æ6%)
AA 26 (61Æ9%) 8 (19Æ1%) 0 (0%)
The number of carriers of each VKORC1:c.)1639G > A genotype, and
the percentage (parentheses) of each genotype for each acenocoumarol
dose are represented.
P for trend, < 0Æ001.
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(90Æ5%) carried the A allele. However, the A allele was less
frequent in the group of 21 patients requiring a high
acenocoumarol dose: among these patients only 6 (28Æ6%)
carried the A allele in the heterozygous form and none of them
carried the AA genotype.
The mean age and the c.430C > T and c.1075A > C variants
of CYP2C9 in the three groups of patients have been reported
previously (Hermida et al, 2002). We showed that both age
and the polymorphisms of CYP2C9, especially the c.1075A > C
variant, influenced the acenocoumarol dose requirements,
while gender and other drugs did not (Hermida et al, 2002).
We fitted logistic regression models to assess the independent
contribution of VKORC1:c.)1639G > A to the inter-individual
variability of the pharmacological response to acenocoumarol,
taking also into account the effect of polymorphisms of
CYP2C9, of age and sex. The results of this analysis are shown
in Table II. The presence of the A allele increased the odds of
requiring a low acenocoumarol dose. This effect was notably
higher when the A allele was present in the homozygous form:
OR 44Æ2 (95% CI 5Æ5–354Æ6; P < 0Æ001). Moreover, an inverse
correlation was seen between the mean weekly dose of
acenocoumarol required and bearing at least one VKORC1:-
c.)1639A allele (b coefficient, )0Æ35; P ¼ 0Æ043) within the low
dose group. Accordingly, not only did the A allele influence the
odds of requiring a low acenocoumarol dose, but it also
exerted an independent effect against requiring a high
acenocoumarol dose.
The sensitivity and specificity of carrying the VKORC1:-
c.)1639A allele for low dose requirements were 90Æ5% (95% CI
77Æ4–97Æ3) and 40% (95% CI 27Æ6–52Æ8) respectively.
Effect of age and the variants of CYP2C9
The effect of age and the c.430C > T and c.1075A > C variants
of CYP2C9 on the acenocoumarol requirement in this
population has been analysed and the results are available
elsewhere (Hermida et al, 2002). However, at the time that
work was carried out, the polymorphisms of the VKORC1 gene
had not yet been identified. For this reason, we updated the
estimates for the independent association between both age
and the variants of CYP2C9 and the odds of requiring a low
acenocoumarol dose after also adjusting for the
VKORC1:c.)1639G > A polymorphism in the multivariate
analysis. As can be observed in Table II, age was still an
independent factor influencing the acenocoumarol dose after
adjusting for the c.)1639G > A polymorphism: every addi-
tional year of age was associated with 16% higher odds of
needing a lower acenocoumarol dose. Bearing the c.430C > T
or c.1075A > C CYP2C9 variants also remained independently
associated with a higher odds of requiring a low acenocouma-
rol dose.
Combined effect of the A allele of VKORC1:c.)1639G > A
and the CYP2C9 variants
Remarkably, within the group requiring low acenocoumarol
doses, all patients (n ¼ 42) were carriers of at least one of the
three polymorphisms analysed. In contrast, among the 21
patients who required a high acenocoumarol dose, 13 of them
(61Æ9%) were free of the three polymorphisms. In the medium
dose group, 36 of 42 subjects carried at least one of the three
polymorphisms. All patients who were simultaneously carriers
of both the VKORC1:c.)1639G > A allele and the CY-
P2C9:c.1075A > C polymorphism (n ¼ 10) required a low
acenocoumarol dose, whereas 11 of 20 patients (55%) carrying
the A allele of VKORC and CYP2C9:c.430C > T belonged to
the low acenocoumarol dose group. When an exact method
(binomial CI) was used to assess the proportion of carriers of
both VKORC1:c.)1639A and CYP2C9:c.1075A > C polymor-
phisms requiring a low acenocoumarol dose, the 95% CI
estimated that 69–100% of patients that carried both muta-
tions would require a low acenocoumarol dose (P < 0Æ001,
Fisher exact test).
Discussion
The recent identification of the VKORC1 gene (Li et al, 2004;
Rost et al, 2004), involved in the vitamin K cycle, has prompted
the search for new polymorphisms that can contribute to
explaining the high interindividual variability in the dose
requirements for oral anticoagulants. Much of this variability
has been found to be due to the VKORC1 genotype. Notably,
37% of the total variability in response to acenocoumarol in a
group of healthy subjects was reported to be attributable to
VKORC1 (Bodin et al, 2005). Although several haplotypes have
been identified in the VKORC1 gene, those including the
c.)1639G > A polymorphism have been associated with vari-
ability in the sensitivity to warfarin or acenocoumarol (Bodin
et al, 2005; D’Andrea et al, 2005; Geisen et al, 2005; Rieder
et al, 2005). Our findings support the importance of the role
Table II. Association of the VKORC1:c.)1639G > A polymorphism,
the c.430C > T and c.1075A > C variants of CYP2C9 and age with the
likelihood of requiring a low (A) or a high (B) dose of acenocoumarol.
Crude
OR
95% CI Adjusted
OR* 95% CI P-value
A: low dose
VKORC1:c.)1639A 2Æ96 0Æ85–10Æ37 9Æ38 1Æ90–46Æ43 0Æ006
CYP2C9 variants 2Æ28 0Æ95–5Æ50 3Æ79 1Æ24–11Æ60 0Æ020
Age (years) 1Æ12 1Æ05–1Æ20 1Æ16 1Æ07–1Æ25 <0Æ001
B: high dose
VKORC1:c.)1639A 0Æ12 0Æ04–0Æ41 0Æ04 0Æ01–0Æ22 <0Æ001
CYP2C9 variants 0Æ21 0Æ04–1Æ07 0Æ06 0Æ01–0Æ62 0Æ017
Age (years) 0Æ94 0Æ89–0Æ99 0Æ90 0Æ84–0Æ97 0Æ005
OR, odds ratio; CI, confidence interval.
*Logistic regression models adjusted for gender and for the other
variables shown in the table. The group of patients taking the medium
dose of acenocoumarol was considered the reference category in both
models.
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played by the genotype c.)1639G > A in the sensitivity to
acenocoumarol. The present study found that carrying the A
allele notably increased the odds of requiring a low acen-
ocoumarol dose to reach an INR within the therapeutic range.
More than 90% of the patients who required a low dose of
acenocoumarol to maintain a therapeutic INR carried the A
allele, while this allelic variant was only present in <30% of the
patients who needed a high dose. This allele was present in 76%
of the patients in the medium dose group. Our findings support
the notion that the association of VKORC1:c.)1639G > A with
the sensitivity to acenocoumarol is larger than that observed
with the CYP2C9 polymorphisms, as the probability of
requiring a low acenocoumarol dose associated with carrying
the A allele was almost three times higher than the probability
associated with the CYP2C9 variants.
Although the characteristics of the present study did not
allow us to determine how the variability differs for each
polymorphism, from our data it can be inferred that
genotyping VKORC1:c.)1639G > A and CYP2C9:
c.1075A > C can help to identify a high percentage of the
patients who can safely commence and maintain their
anticoagulation on a low dose of acenocoumarol without risk
of experiencing a bleeding episode. The 10 patients who
simultaneously carried the A allele of VKORC1:c.)1639A > G
and CYP2C9:c.1075A > C required a low dose of acenocouma-
rol for stable anticoagulation. Accordingly, among the 42
consecutive patients who entered the study because they
required a low dose of acenocoumarol, 40 of them carried at
least one of the two polymorphisms.
Our findings could be relevant when applied to clinical
practice: as it has been suggested that the hyper-responsiveness
to oral anticoagulant is linked to high risk of bleeding at the
beginning of treatment, patients to be treated with acen-
ocoumarol and bearing the c.)1639G > A polymorphism of
VKORC1 should start treatment with a reduced initial
‘loading’ dose in order to avoid over-anticoagulation and
subsequent bleeding risk, particularly if they also carry the
c.1075A > C variant of CYP2C9. An algorithm to calculate the
daily dose of warfarin taking into account the VKORC1
genotype has recently been proposed (Sconce et al, 2005). The
present study could not build an algorithm because our
population was not randomly selected.
The higher sensitivity to coumarin derivatives in the
presence of the A allele of the VKORC1:c.)1639G > A
polymorphism is probably due to a lower amount of VKORC1
in these patients, which would lead to a decrease in the
availability of vitamin K-hydroquinone: recently, an associ-
ation between low hepatic VKORC1 mRNA levels and
haplotypes of the VKORC1 gene carrying the )1639A allele
has been shown, such patients being particularly sensitive to
warfarin (Rieder et al, 2005).
This study has limitations: the sample size, although large
enough to draw conclusions, was not sufficient to avoid wide
CI; on the other hand, the patients were not randomly selected
but chosen according to predefined groups (i.e. low, medium
and high acenocoumarol dose requirements). Hence, our
results cannot be directly applied to the general population of
patients receiving anticoagulants. Nonetheless, the strength of
the association between the VKORC1:c.)1639G > A poly-
morphism and the acenocoumarol requirements undoubtedly
underlines the importance of this genetic variant as a major
determinant of the sensitivity to acenocoumarol in patients
under anticoagulant treatment.
In conclusion, for the first time the association between the
c.)1639G > A polymorphism of the VKORC1 gene and the
acenocoumarol requirement for stable long-term anticoagula-
tion has been studied. The A allele increases the likelihood of
requiring a low dose of acenocoumarol, especially when the
c.1075A > C variant of the CYP2C9 gene is also present.
Genotyping for both mutations should make it possible to
identify the vast majority of patients that are likely to require a
low dosage of acenocoumarol.
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